167 related articles for article (PubMed ID: 29277498)
1. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus.
Zipori AB; Tehrani NN; Ali A
J AAPOS; 2018 Feb; 22(1):76-79. PubMed ID: 29277498
[TBL] [Abstract][Full Text] [Related]
2. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
[TBL] [Abstract][Full Text] [Related]
3. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
Appalla D; Depalma A; Calderwood S
Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
5. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
[TBL] [Abstract][Full Text] [Related]
6. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
Jiang T; Du J; Raynald ; Wang J; Li C
World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
[TBL] [Abstract][Full Text] [Related]
7. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
[TBL] [Abstract][Full Text] [Related]
8. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
[TBL] [Abstract][Full Text] [Related]
9. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.
Goyer I; Dahdah N; Major P
Pediatr Neurol; 2015 Apr; 52(4):450-3. PubMed ID: 25682485
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
11. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
[TBL] [Abstract][Full Text] [Related]
13. Everolimus tablets for patients with subependymal giant cell astrocytoma.
Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
[TBL] [Abstract][Full Text] [Related]
14. Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.
Fukumura S; Watanabe T; Takayama R; Minagawa K; Tsutsumi H
J Child Neurol; 2015 Aug; 30(9):1192-5. PubMed ID: 25143481
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
[TBL] [Abstract][Full Text] [Related]
16. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
[TBL] [Abstract][Full Text] [Related]
17. Everolimus treatment among patients with tuberous sclerosis affects serum lipid profile.
Trelińska J; Dachowska I; Kotulska K; Jóźwiak S; Fendler W; Młynarski W
Pharmacol Rep; 2016 Oct; 68(5):1002-7. PubMed ID: 27423526
[TBL] [Abstract][Full Text] [Related]
18. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
Jóźwiak S; Nabbout R; Curatolo P;
Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
[TBL] [Abstract][Full Text] [Related]
19. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
[TBL] [Abstract][Full Text] [Related]
20. Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus.
Arroyo MS; Krueger DA; Broomall E; Stevenson CB; Franz DN
Pediatr Neurol; 2017 Jul; 72():81-85. PubMed ID: 28511812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]